NAZARTINIB FOR USE IN THE TREATMENT OF CNS METASTASIS Russian patent published in 2023 - IPC A61K31/55 A61P35/00 A61P35/04 

FIELD: medicine.

SUBSTANCE: oncology, intended for the treatment of metastases in a patient with non-small cell lung cancer (NSCLC). Nazartinib or a pharmaceutically acceptable salt thereof is used to treat or prevent metastasis in a patient that is central nervous system (CNS) metastasis, brain metastasis, or leptomeningeal metastasis resulting from a primary lesion such as non-small cell lung cancer (NSCLC) and where NSCLC is characterized by the presence of an EGFR mutation (deletion in exon 19 or substitution (L858R) in exon 21). In other embodiments, methods are provided for treating metastases in a patient with NSCLC, wherein the metastases are selected from central nervous system (CNS) metastases, brain metastases, and leptomeningeal metastases, comprising administering a therapeutically effective amount of nazartinib or a pharmaceutically acceptable salt thereof to the patient.

EFFECT: improving the efficiency of treatment or prevention of malignant neoplasms in the central nervous system and in relation to brain lesions in patients with NSCLC with EGFR mutation, including patients with initial brain metastases, and also provides a good quality of life for patients suffering from NSCLC.

22 cl, 1 dwg, 9 tbl, 3 ex